ART-123 Asahi Kasei.
Article Details
- CitationCopy to clipboard
Khorchidi S, Bantleon R, Kehlbach R, Tepe G, Wiskirchen J, Duda SH
ART-123 Asahi Kasei.
Curr Opin Investig Drugs. 2002 Aug;3(8):1196-8.
- PubMed ID
- 12211414 [ View in PubMed]
- Abstract
Asahi Kasei is developing a recombinant thrombomodulin (ART-123), a human protein with both thrombin inhibiting and protein C stimulating activities, for the potential treatment of thromboembolism and blood clotting disorders, such as disseminated intravascular thromboembolism [169907]. By September 2000, it had entered phase III trials [383525]. A patent, US-05916874, claiming a method for treating liver injury and whose composition comprises a thrombomodulin, was published in 1999 by the company.
DrugBank Data that Cites this Article
- Drugs